G01N 2333/70503
Immunoglobulin superfamily
Official title: Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
G01N2333/70503 (Immunoglobulin superfamily) appears on 1,215 US grants and 2,569 published applications in this corpus.
Search patents in G01N- Granted patents
- 1,215
- Published applications
- 2,569
- Assignees
- 1,104
- Inventors
- 4,844
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 2 | 0 |
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 11 | 0 |
| 1999 | 5 | 0 |
| 2000 | 3 | 0 |
| 2001 | 5 | 1 |
| 2002 | 6 | 21 |
| 2003 | 3 | 28 |
| 2004 | 10 | 37 |
| 2005 | 5 | 32 |
| 2006 | 9 | 26 |
| 2007 | 9 | 37 |
| 2008 | 12 | 42 |
| 2009 | 14 | 52 |
| 2010 | 23 | 54 |
| 2011 | 17 | 68 |
| 2012 | 21 | 66 |
| 2013 | 23 | 47 |
| 2014 | 34 | 83 |
| 2015 | 51 | 154 |
| 2016 | 47 | 176 |
| 2017 | 68 | 175 |
| 2018 | 113 | 167 |
| 2019 | 128 | 164 |
| 2020 | 113 | 175 |
| 2021 | 90 | 175 |
| 2022 | 83 | 159 |
| 2023 | 77 | 155 |
| 2024 | 85 | 151 |
| 2025 | 94 | 197 |
| 2026 | 50 | 127 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- G01N 2333/70539Mhc-moleculesIndexing code359
- G01N 2333/7051T-cell receptor -cd3 complexIndexing code210
- G01N 2333/70514Cd4Indexing code155
- G01N 2333/70517Cd8Indexing code125
- G01N 2333/70532B7 moleculesIndexing code122
- G01N 2333/70535Fc-receptorsIndexing code109
- G01N 2333/70525Icam moleculesIndexing code54
- G01N 2333/70521Cd28, cd152Indexing code43
All 11 subgroupsShow fewer
Recent patents
- Multi-domain CD1a antagonist/PD-1 agonist antibody molecules15 Sep 2026US 12,735,491 B2Immunocore Limited
- Reagent composition for immunophenotyping of B lymphoblastic leukemia/lymphoma and use thereof8 Sep 2026US 12,730,107 B2
- Methods for determining differences in alpha-4 integrin activity by correlating differences in sVCAM and/or sMAdCAM levels25 Aug 2026US 12,716,899 B2Biogen MA Inc.
- African swine fever DIVA immunoassay18 Aug 2026US 12,710,423 B2Intervet Inc.
- Antibody blocking human FcγRIIIA and FcγRIIIB4 Aug 2026US 12,698,331 B2Centre National de la Recherche Scientifique (CNRS)
- Mhc class i molecules8 Oct 2026US 2026/0308228 A1Immudex ApS
- Multi-domain molecules8 Oct 2026US 2026/0308260 A1Immunocore Limited
- Compositions and methods for determining the effects of t cell engager8 Oct 2026US 2026/0309708 A1Arbele Limited
- B7-h4 therapeutic binding molecules for the treatment of cancer1 Oct 2026US 2026/0295065 A1MedImmune, LLC
- Anti-pd-l1 nanobody, preparation method therefor and use thereof1 Oct 2026US 2026/0297195 A1Kanglitai Biomedical (Qingdao) Co., Ltd.
Most cited
By later US patents
- Downmodulating an immune response with multivalent antibodies to PD-1309US 6,808,710 B1Dana-Farber Cancer Institute, Inc. · 2004
- Identification and engineering of antibodies with variant Fc regions and methods of using same227US 7,355,008 B2MacroGenics, Inc. · 2008
- PD-1, a receptor for B7-4, and uses therefor156US 7,101,550 B2Dana-Farber Cancer Institute, Inc. · 2006
- Tolerogenic synthetic nanocarriers for inducing regulatory B cells129US 8,652,487 B2Selecta Biosciences, Inc. · 2014
- Methods for screening for compounds that modulate pd-1 signaling113US 7,105,328 B2Dana-Farber Cancer Institute, Inc. · 2006